Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (34 quarters reported)
$582M in Q1 2018 → $1.93B now. Hover for any quarter.
As reported for the quarter ended June 30, 2026. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Natera Inc | 21.8% | Unchanged | 1,550,280 | $421M |
| Vera Therapeutics Inc | 6.2% | Unchanged | 2,793,987 | $120M |
| Genmab A/s | 5.7% | Added 438% | 4,045,215 | $111M |
| Jazz Pharmaceuticals PLC | 4.6% | Trimmed 39% | 365,341 | $88M |
| Rapport Therapeutics Inc | 4.1% | Unchanged | 1,904,408 | $79.4M |
| Seaport Therapeutics Inc | 4.0% | New | 3,564,871 | $77.4M |
| Arrivent Biopharma Inc | 3.0% | Unchanged | 1,696,752 | $58.9M |
| UP Ultragenyx Pharmaceutical In | 3.0% | Trimmed 45% | 1,717,505 | $57.3M |
| Bioage Labs Inc | 2.9% | Unchanged | 2,293,788 | $56.2M |
| Bristol-myers Squibb Co | 2.6% | Trimmed 56% | 876,970 | $50.5M |
| Supernus Pharmaceuticals | 2.5% | Added 8.6% | 1,036,328 | $48.2M |
| Rhythm Pharmaceuticals Inc | 2.3% | Trimmed 9.3% | 408,027 | $45.3M |
| Gilead Sciences Inc | 2.2% | New | 343,100 | $43.3M |
| UT United Therapeutics Corp Del | 2.1% | Trimmed 52% | 76,489 | $41.4M |
| Cogent Biosciences Inc | 2.1% | Trimmed 51% | 1,035,148 | $40.1M |
| Axsome Therapeutics Inc. | 2.0% | Trimmed 25% | 160,429 | $39.3M |
| Immatics N.v | 1.9% | Added 1.1% | 3,669,346 | $37.2M |
| Dyne Therapeutics Inc | 1.9% | Added 1.5% | 1,658,384 | $36.8M |
| Immunome Inc | 1.9% | Added 1.1% | 1,720,316 | $36.5M |
| Ideaya Biosciences Inc | 1.8% | Trimmed 18% | 925,119 | $34.5M |
| Anaptysbio Inc | 1.7% | Added 99% | 493,536 | $33.3M |
| Nektar Therapeutics | 1.7% | Trimmed 7.4% | 471,763 | $32.9M |
| Pharvaris N V | 1.6% | Added 7.7% | 881,299 | $30.5M |
| Arcus Biosciences Inc | 1.5% | Added 2.4% | 945,690 | $29.2M |
| Inhibrx Biosciences Inc | 1.5% | Trimmed 25% | 303,103 | $28.7M |
| Biomarin Pharmaceutical Inc | 1.1% | Trimmed 54% | 358,568 | $20.5M |
| Veradermics Inc | 0.9% | Added 103% | 148,993 | $18.3M |
| Alcon Ag | 0.9% | Trimmed 65% | 255,824 | $17.2M |
| Insmed Inc | 0.9% | Trimmed 54% | 158,398 | $16.9M |
| UP Ultragenyx Pharmaceutical In Call | 0.9% | Added 43% | 500,000 | $16.7M |
| Intuitive Surgical Inc Call | 0.8% | New | 40,000 | $15.9M |
| GM Globus Med Inc Call | 0.8% | New | 200,000 | $15.8M |
| Edgewise Therapeutics Inc | 0.8% | Trimmed 1.4% | 380,923 | $15.5M |
| Exelixis Inc Put | 0.7% | Added 1.1% | 254,200 | $13.8M |
| Nurix Therapeutics Inc | 0.7% | New | 524,098 | $12.7M |
| Design Therapeutics Inc | 0.6% | New | 865,135 | $12.5M |
| Definium Therapeutics Inc | 0.6% | Trimmed 26% | 255,903 | $12M |
| First Tracks Biotherapeutics | 0.6% | New | 565,199 | $11.4M |
| Abbott Laboratories | 0.6% | New | 122,998 | $11.2M |
| Disc Medicine Inc | 0.6% | Added 87% | 146,239 | $10.7M |
| Tenax Therapeutics Inc | 0.4% | Added 379% | 500,039 | $7.28M |
| Sionna Therapeutics Inc | 0.3% | New | 144,432 | $6.35M |
| Absci Corporation | 0.2% | New | 337,400 | $3.91M |
| Mirum Pharmaceuticals Inc | 0.2% | Unchanged | 27,591 | $3.23M |
| Jade Biosciences Inc | 0.1% | Unchanged | 107,391 | $2.39M |
| Savara Inc | 0.1% | Unchanged | 364,763 | $2.25M |
| PP Praxis Precision Medicines I | 0.1% | Trimmed 90% | 6,440 | $2.16M |
| Septerna Inc | 0.1% | Unchanged | 47,506 | $1.59M |
| Onkure Therapeutics Inc | 0.1% | Added 127% | 321,692 | $1.47M |
| Sagimet Biosciences Inc | 0.1% | New | 166,667 | $1.29M |
| Wave Life Sciences Ltd | 0.1% | Unchanged | 189,253 | $1.1M |
| Aktis Oncology Inc | 0.1% | New | 32,436 | $1.05M |
| Tyra Biosciences Inc | 0.1% | Trimmed 84% | 32,267 | $1.03M |
| Bolt Biotherapeutics Inc | 0.0% | Unchanged | 137,721 | $530K |
| Nextcure Inc | 0.0% | Unchanged | 222,654 | $356K |
| Imagenebio Inc | 0.0% | Unchanged | 31,884 | $188K |
| Heartflow Inc | 0.0% | New | 5,079 | $149K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended June 30, 2026 · filed August 14, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IT Ishares Tr | Exited | −600,000 | −$149M | — |
| SS SPDR Series Trust | Exited | −1,050,000 | −$134M | — |
| Genmab A/s | Added | +3,292,954 | +$90.5M | 5.7% |
| Astrazeneca PLC | Exited | −456,031 | −$89.9M | — |
| IQ Invesco Qqq Tr | Exited | −150,000 | −$86.6M | — |
| IT Ishares Tr | Exited | −475,000 | −$80.2M | — |
| Seaport Therapeutics Inc | New | +3,564,871 | +$77.4M | 4.0% |
| Bristol-myers Squibb Co | Trimmed | −1,111,751 | −$64.1M | 2.6% |
| Jazz Pharmaceuticals PLC | Trimmed | −232,986 | −$56.1M | 4.6% |
| UP Ultragenyx Pharmaceutical In | Trimmed | −1,428,383 | −$47.7M | 3.0% |
Showing the 10 largest of 74 changes.
quarter ended March 31, 2026 · filed May 15, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Astrazeneca PLC | Exited | −1,632,334 | −$150M | — |
| IT Ishares Tr | New | +600,000 | +$149M | 5.7% |
| SS SPDR Series Trust | New | +1,050,000 | +$134M | 5.1% |
| Astrazeneca PLC | New | +456,031 | +$89.9M | 3.4% |
| IQ Invesco Qqq Tr | New | +150,000 | +$86.6M | 3.3% |
| IT Ishares Tr | New | +475,000 | +$80.2M | 3.0% |
| Vertex Pharmaceuticals Inc | Exited | −164,594 | −$74.6M | — |
| Abbvie Inc | Exited | −317,783 | −$72.6M | — |
| Intuitive Surgical Inc | Exited | −126,968 | −$71.9M | — |
| Jazz Pharmaceuticals PLC | Trimmed | −361,533 | −$68.3M | 4.3% |
Showing the 10 largest of 81 changes.
quarter ended December 31, 2025 · filed February 13, 2026
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc | Exited | −1,252,312 | −$139M | — |
| Bristol-myers Squibb Co | New | +1,512,994 | +$81.6M | 3.5% |
| Astrazeneca PLC | Added | +808,401 | +$74.3M | 6.5% |
| Axsome Therapeutics Inc | Trimmed | −381,233 | −$69.6M | 0.1% |
| EL Eli Lilly & Co | New | +61,652 | +$66.3M | 2.9% |
| Jazz Pharmaceuticals PLC | Added | +371,032 | +$63.1M | 7.0% |
| Boston Scientific Corp | Exited | −569,427 | −$55.6M | — |
| Roivant Sciences Ltd | Trimmed | −2,414,688 | −$52.4M | 0.7% |
| IT Ishares Tr | Exited | −325,000 | −$46.9M | — |
| Biomarin Pharmaceutical Inc | New | +697,133 | +$41.4M | 1.8% |
Showing the 10 largest of 65 changes.
quarter ended September 30, 2025 · filed November 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| UN Uniqure Nv | Trimmed | −1,421,494 | −$83M | 0.4% |
| Eli Lilly And Co | Exited | −97,018 | −$75.6M | — |
| IT Ishares Tr | Exited | −250,000 | −$53.9M | — |
| Vertex Pharmaceuticals Inc | New | +117,875 | +$46.2M | 2.5% |
| United Therapeutics Corp | New | +97,100 | +$40.7M | 2.2% |
| Astrazeneca PLC | Added | +530,272 | +$40.7M | 3.5% |
| SS SPDR Series Trust | New | +400,000 | +$40.1M | 2.2% |
| Axsome Therapeutics Inc | Added | +299,889 | +$36.4M | 2.6% |
| Rhythm Pharmaceuticals Inc | Trimmed | −339,044 | −$34.2M | 1.4% |
| Ideaya Biosciences Inc | Trimmed | −1,225,100 | −$33.3M | 1.4% |
Showing the 10 largest of 72 changes.
quarter ended June 30, 2025 · filed August 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Stryker Corporation | Exited | −298,567 | −$111M | — |
| IQ Invesco Qqq Tr | Exited | −175,000 | −$82.1M | — |
| Gilead Sciences Inc | Added | +631,408 | +$70M | 7.1% |
| Medtronic PLC | Exited | −562,992 | −$50.6M | — |
| Abbvie Inc | New | +265,850 | +$49.3M | 3.0% |
| Alnylam Pharmaceuticals Inc | Exited | −176,181 | −$47.6M | — |
| IT Ishares Tr | New | +375,000 | +$47.4M | 2.9% |
| Boston Scientific Corp | New | +431,200 | +$46.3M | 2.8% |
| Soleno Therapeutics Inc | Exited | −529,300 | −$37.8M | — |
| Eli Lilly And Co | Added | +44,218 | +$34.5M | 4.6% |
Showing the 10 largest of 73 changes.
quarter ended March 31, 2025 · filed May 15, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IQ Invesco Qqq Tr | New | +175,000 | +$82.1M | 5.4% |
| IT Ishares Tr | New | +350,000 | +$69.8M | 4.6% |
| Stryker Corporation | Added | +182,562 | +$68M | 7.3% |
| Abbvie Inc | Exited | −359,393 | −$63.9M | — |
| Medtronic PLC | New | +562,992 | +$50.6M | 3.3% |
| Astrazeneca PLC | Exited | −651,344 | −$42.7M | — |
| Gilead Sciences Inc | Trimmed | −355,327 | −$39.8M | 3.1% |
| Soleno Therapeutics Inc | New | +529,300 | +$37.8M | 2.5% |
| Axsome Therapeutics Inc | Trimmed | −316,409 | −$36.9M | 1.3% |
| EL Eli Lilly & Co | Added | +38,436 | +$31.7M | 2.8% |
Showing the 10 largest of 70 changes.
quarter ended December 31, 2024 · filed February 14, 2025
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| NA Novo-nordisk A S | Exited | −726,329 | −$86.5M | — |
| Gilead Sciences Inc | New | +774,227 | +$71.5M | 5.2% |
| Abbvie Inc | New | +359,393 | +$63.9M | 4.7% |
| Sarepta Therapeutics Inc | New | +428,771 | +$52.1M | 3.8% |
| Elanco Animal Health Inc | Exited | −3,518,684 | −$51.7M | — |
| Stryker Corporation | New | +116,005 | +$41.8M | 3.0% |
| Jazz Pharmaceuticals PLC | Added | +315,631 | +$38.9M | 4.5% |
| Replimune Group Inc | Added | +3,101,384 | +$37.6M | 2.8% |
| Alnylam Pharmaceuticals Inc | New | +110,157 | +$25.9M | 1.9% |
| Alkermes PLC | New | +894,266 | +$25.7M | 1.9% |
Showing the 10 largest of 67 changes.
quarter ended September 30, 2024 · filed November 13, 2024
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| IQ Invesco Qqq Tr | Exited | −400,000 | −$192M | — |
| Ascendis Pharma A/s | Exited | −734,284 | −$100M | — |
| Stryker Corporation | Exited | −193,084 | −$65.7M | — |
| Align Technology Inc | Exited | −218,524 | −$52.8M | — |
| Bioage Labs Inc | New | +2,304,901 | +$47.9M | 3.8% |
| Incyte Corp | New | +714,176 | +$47.2M | 3.7% |
| Edwards Lifesciences Corp | Exited | −500,000 | −$46.2M | — |
| AL Abbott Labs | Exited | −390,200 | −$40.5M | — |
| Intuitive Surgical Inc | Exited | −87,217 | −$38.8M | — |
| Alnylam Pharmaceuticals Inc | Exited | −147,929 | −$35.9M | — |
Showing the 10 largest of 86 changes.
Loading...
